ClinicalTrials.gg

Program

RD06-05

A development code. Also written as “RD06-05 CART Cell Injection” and “RD06-05 CAR-T Cell Injection”.

Its studies are mostly in Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis · Lupus Erythematosus, Systemic · Scleroderma, Systemic, led by Nanjing Bioheng Biotech.

Furthest: early phase 1, since Jan 9, 20253 company-led studies, 3 open or runningNext primary completion: Jan 1, 2027 (early phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Nanjing Bioheng Biotech33 open or runningearly phase 1since Jan 9, 2025Jan 9, 2025Jan 1, 2027early phase 1 · NCT06775912

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jan 9, 2025First study: early phase 1 study in Scleroderma, SystemicFirst studyNCT06775912 · 18 planned · China
  2. Sep 23, 2025Early phase 1 study in Anti-Neutrophil Cytoplasmic Antibody-Associated VasculitisNCT07203404 · 96 planned · China
  3. Apr 7, 2026Early phase 1 study in Lupus Erythematosus, SystemicNCT07596680 · 30 planned · China

Ahead

  1. Jan 1, 2027Primary completion: early phase 1 study in Scleroderma, SystemicNCT06775912
  2. Jul 23, 2027Primary completion: early phase 1 study in Anti-Neutrophil Cytoplasmic Antibody-Associated VasculitisNCT07203404
  3. Apr 30, 2028Primary completion: early phase 1 study in Lupus Erythematosus, SystemicNCT07596680

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07596680Lupus Erythematosus, Systemic · ChinaEarly 1Not yet recruitingApr 30, 202830
NCT07203404Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis · ChinaEarly 1RecruitingJul 23, 202796
NCT06775912Scleroderma, Systemic · ChinaEarly 1RecruitingJan 1, 202718

How it is read

Names in the registry

  • “RD06-05 CART Cell Injection”, 2 entries
  • “RD06-05 CAR-T Cell Injection”, 1 entry

Codes read as this program: RD0605.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.